Acne vulgaris is a chronic inflammatory disease among the most common dermatological conditions worldwide (~9% prevalence) (Global Burden of Disease figures). Acne already affects mainly adolescents, (~90% prevalence) but it can last into adulthood, especially for women. Importantly, in adolescents, around 20-35% of cases, can be moderate-to-severe for which current treatments have many pitfalls. Persistent acne can have a profound effect on an individuals self-esteem and confidence thus resulting in significant morbidity. Recent data also suggests acne is becoming more prevalent (Zhu Z et al 2025).
A therapeutic acne vulgaris vaccine could have utility as a monotherapy or an adjunct to existing therapies. It should significantly reduce both inflammatory and non-inflammatory acne lesions by targeting relevant antigens on pathogenic strains of Cutibacterium acnes, C.acnes, a known contributor to clinical disease. The vaccine industry is now turning its attention to acne with a new mRNA-basedC.acnes approach in Phase 1/2 testing (Sanofi Pasteur, SP0268).
This MarketVIEW product is a comprehensive Executive Presentation (>200 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls) which forecasts the commercial potential of an acne vulgaris therapeutic vaccine across 10 developed markets (split by age/gender) to 2045. The interactive model allows changes to product administration, uptake, coverage, pricing and acne severity. The analysis also contains a thorough up-to-date review of acne epidemiology, current treatments/guidelines and the potential positioning of a new acne vaccine.
THIS PRODUCT IS A SUMMARY PRESENTATION (~200 slides, .pdf) + 2 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): iSTOCK images
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
